Vident Investment Advisory, LLC Merus N.V. Transaction History

Vident Investment Advisory, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$14.25 - $20.5 $27,730 - $39,893	-1,946 Reduced 3.54%	53,056 $976,000
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $296,243 - $547,587	23,144 Added 72.65%	55,002 $850,000
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $63,636 - $98,767	-3,414 Reduced 9.68%	31,858 $638,000
Q2 2022 Aug 15, 2022	SELL	$13.98 - $29.25 $35,271 - $73,797	-2,523 Reduced 6.68%	35,272 $799,000
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $148,554 - $194,733	6,300 Added 20.0%	37,795 $999,000
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $629,900 - $1.02 Million	31,495 New	31,495 $1 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.